Synaptic Systems

Cat. No.: HS-361 003

Amount: 200 µl

Price: $380.00

Cat. No. HS-361 003	200 µl specific antibody, lyophilized. Affinity purified with the immunogen. Azide was added before lyophilization. For reconstitution add 200 µl H₂O. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Applications	WB: 1 : 1000 (AP-staining) gallery IP: not tested yet ICC: not tested yet IHC: 1 : 100 (see remarks) gallery IHC-P: 1 : 100 gallery IHC-Fr: 1 : 100 (see remarks) gallery
Immunogen	Synthetic peptide corresponding to AA 230 to 247 from mouse CD8a (UniProt Id: P01731)
Reactivity	Reacts with: mouse (P01731). Weaker signal: rat. No signal: human. Other species not tested yet.
Remarks	IHC: Heat-mediated antigen retrieval (in citrate buffer pH 6) is required for immunohistochemical staining. IHC-Fr: MeOH fixation is recommended.
Data sheet	hs-361_003.pdf

Important information
This product belongs to the HistoSure product line of antibodies developed for and extensively tested in FFPE tissues.
For more information please visit our HistoSure brand website.

References for CD8a - HS-361 003

IHC (2)
IHC-P (11)

MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody.
Lee PJ, Hung CM, Yang AJ, Hou CY, Chou HW, Chang YC, Chu WC, Huang WY, Kuo WC, Yang CC, Lin KI, et al.
Gut microbes (2024) 161: 2380061. HS-361 003 IHC; tested species: mouse

Common germline variants of the human APOE gene modulate melanoma progression and survival.
Ostendorf BN, Bilanovic J, Adaku N, Tafreshian KN, Tavora B, Vaughan RD, Tavazoie SF
Nature medicine (2020) : . HS-361 003 IHC; tested species: mouse

Nanostructured lipid carriers based mRNA vaccine leads to a T cell-inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model.
Fournier C, Mercey-Ressejac M, Derangère V, Al Kadi A, Rageot D, Charrat C, Leroy A, Vollaire J, Josserand V, Escudé M, Escaich S, et al.
EBioMedicine (2025) 112: 105543. HS-361 003 IHC-P; tested species: mouse

Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA, Gubser PM, Sethumadhavan S, Kersbergen A, Negrón Abril YL, Goldford J, Sellers K, Abeysekera W, Garnham AL, McDonald JA, Weeden CE, et al.
Cell metabolism (2022) : . HS-361 003 IHC-P; tested species: mouse

WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Taniguchi H, Caeser R, Chavan SS, Zhan YA, Chow A, Manoj P, Uddin F, Kitai H, Qu R, Hayatt O, Shah NS, et al.
Cell reports (2022) 397: 110814. HS-361 003 IHC-P; tested species: mouse

Genomic control of inflammation in experimental atopic dermatitis.
Liu Y, Zienkiewicz J, Qiao H, Gibson-Corley KN, Boyd KL, Veach RA, Hawiger J
Scientific reports (2022) 121: 18891. HS-361 003 IHC-P; tested species: mouse

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, et al.
Cancer cell (2022) 402: 136-152.e12. HS-361 003 IHC-P; tested species: mouse

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.
Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, et al.
Journal for immunotherapy of cancer (2021) 96: . HS-361 003 IHC-P; tested species: mouse

Loss of Setd4 delays radiation-induced thymic lymphoma in mice.
Feng X, Lu H, Yue J, Schneider N, Liu J, Denzin LK, Chan CS, De S, Shen Z
DNA repair (2020) 86: 102754. HS-361 003 IHC-P; tested species: mouse

Glioma escape signature and clonal development under immune pressure.
Maire CL, Mohme M, Bockmayr M, Fita KD, Riecken K, Börnigen D, Alawi M, Failla AV, Kolbe K, Zapf S, Holz M, et al.
The Journal of clinical investigation (2020) : . HS-361 003 IHC-P; tested species: mouse

Therapeutic Targeting of Stat3 Using Lipopolyplex Nanoparticle-Formulated siRNA in a Syngeneic Orthotopic Mouse Glioma Model.
Linder B, Weirauch U, Ewe A, Uhmann A, Seifert V, Mittelbronn M, Harter PN, Aigner A, Kögel D
Cancers (2019) 113: . HS-361 003 IHC-P; tested species: mouse

Immunosuppressive Myeloid Cells' Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy.
Kamran N, Kadiyala P, Saxena M, Candolfi M, Li Y, Moreno-Ayala MA, Raja N, Shah D, Lowenstein PR, Castro MG
Molecular therapy : the journal of the American Society of Gene Therapy (2017) 251: 232-248. HS-361 003 IHC-P

PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Wang J, Xie T, Wang B, William WN, Heymach JV, El-Naggar AK, Myers JN, Caulin C
Cancer prevention research (Philadelphia, Pa.) (2017) 1012: 684-693. HS-361 003 IHC-P

Cat. No.: HS-361 003

Amount: 200 µl

Price: $380.00

References
IHC (2)
IHC-P (11)

IHC

IHC-P

IHC-Fr

Background

CD 8 is a heterodimeric T-cell surface glycoprotein that consists of a CD 8a (alpha) and beta chain. It identifies cytotoxic/suppressor T-cells that interact with MHC class I bearing targets. CD 8 is thought to play a role in the process of T-cell mediated killing. CD 8 alpha chains binds to class I MHC molecules alpha-3 domains.

1 ) Frost EL et al., J. Immunol. (2015)
2 ) Wu RC et al., Oncoimmunology (2012)
3 ) Hyland L et al., Virology (1994)
4 ) Prince HE et al., Diagn Clin Immunol (1987)
5 ) Gaudernack G et al., J. Immunol. Methods (1986)
6 ) Fleischer B et al., J. Immunol. (1986)

Other products for this target

CD8a antibody mouse specific - HS-361 003

References for CD8a - HS-361 003